Patients with estrogen receptor–positive, #HER2 -negative advanced #BreastCancer experienced significantly longer progression-free survival when treated with an oral #CombinationTherapy that included #giredestrant, a next-generation selective #EstrogenReceptor degrader and complete antagonist.

#EliLilly's bid to dominate the next generation of #weightlosstherapies has been strengthened by data on a new #combinationtherapy that combines its GIP/GLP-1 agonist tirzepatide with amylin-targeting eloralintide.

pharmaphorum.com/news/new-lil...